N-[3-(4-Ethyl-benzenesulfonylamino)-2-hydroxy-indan-5-yl]-3-methoxy-benzamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-[3-(4-Ethyl-benzenesulfonylamino)-2-hydroxy-indan-5-yl]-3-methoxy-benzamide
• 英文别名: N-[(2R,3R)-3-[(4-ethylphenyl)sulfonylamino]-2-hydroxy-2,3-dihydro-1H-inden-5-yl]-3-methoxybenzamide
• 化学式: C₂₅H₂₆N₂O₅S
• 分子量: 466.558
• InChiKey: KCRNOVULDSNKBZ-DNQXCXABSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  33
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  113
• 氢给体数：
  3
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  茚满 在 ammonium hydroxide 、 sodium tetrahydroborate 、 硫酸 、 硝酸 、 对甲苯磺酸 、 三乙胺 、 间氯过氧苯甲酸 、 tin(ll) chloride 作用下， 以 甲醇 、 乙醇 、 二氯甲烷 、 甲苯 为溶剂， 反应 2.0h， 生成 N-[3-(4-Ethyl-benzenesulfonylamino)-2-hydroxy-indan-5-yl]-3-methoxy-benzamide
  参考文献：
  名称：

  Aryl sulfonamido indane inhibitors of the Kv1.5 ion channel

  摘要：

  A collection of aryl sulfonamido indanes based on the lead compound I was synthesized and evaluated for Kv1.5 inhibitory activity. Kv1.5 inhibitors have the potential to be atrium-selective agents for treatment of atrial fibrillation. (1R,2R)-1 has an IC50 of 0.033 mu M against Kv1.5 and is selective against other cardiac ion channels, including hERG. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.02.052

文献信息

• US20140342406A1
  申请人：——

  公开号：US20140342406A1

  公开（公告）日：2014-11-20
• ANTIBODIES TO ION CHANNELS
  申请人：UCB BIOPHARMA SPRL

  公开号：US20150203571A1

  公开（公告）日：2015-07-23

  An anti-E1 ion channel antibody or binding fragment thereof, pharmaceutical compositions comprising said antibodies, use of the antibodies and compositions comprising the same, in treatment, for example in the treatment/modulation of pain and processes for generating and preparing said antibodies.
• FUNCTION MODIFYING NAv1.7 ANTIBODIES
  申请人：UCB BIOPHARMA SPRL

  公开号：US20150232553A1

  公开（公告）日：2015-08-20

  A Na v 1.7 binding entity that after binding functionally modifies the activity of the ion channel, in particular an anti-Na v 1.7 antibody or binding fragment thereof, pharmaceutical compositions comprising said antibodies, use of the antibodies and compositions comprising the same, in treatment, for example in the treatment/modulation of pain and processes for generating and preparing said antibodies.
• METHODS OF TREATING PAIN USING FUNCTION MODIFYING NAv1.7 ANTIBODIES
  申请人：UCB Biopharma SPRL

  公开号：US20160222107A1

  公开（公告）日：2016-08-04

  A Na v 1.7 binding entity that after binding functionally modifies the activity of the ion channel, in particular an anti-Na v 1.7 antibody or binding fragment thereof, pharmaceutical compositions comprising said antibodies, use of the antibodies and compositions comprising the same, in treatment, for example in the treatment/modulation of pain and processes for generating and preparing said antibodies.
• US8734798B2
  申请人：——

  公开号：US8734798B2

  公开（公告）日：2014-05-27